Sulthiame
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Sulthiame. Sulthiame is a sulphonamide. It is a central carbonic anhydrase inhibitor. It also blocks sodium channels. Fully referenced neurology checklist.
Mode of action
- Sulthiame is a sulphonamide
- It is a central carbonic anhydrase inhibitor
- It also blocks sodium channels
Indications (adjunctive)
Locked: subscribe to see this section.
Dosing
Locked: subscribe to see this section.
Drugs whose blood levels are increased by Sulthiame
Locked: subscribe to see this section.
Neurological side effects
Locked: subscribe to see this section.
Systemic side effects
Locked: subscribe to see this section.
References
- Fejerman N, Caraballo R, Cersósimo R, Ferraro SM, Galicchio S, Amartino H. Sulthiame add-on therapy in children with focal epilepsies associated with encephalopathy related to electrical status epilepticus during slow sleep (ESES). Epilepsia 2012; 53:1156-1161.
- Gorman KM, Shahwan A. Sultiame revisited: treatment of refractory absence seizures. Epileptic Disord 2016; 18:329-333.
- Milburn-McNulty P, Powell G, Sills GJ, Marson AG. Sulthiame add-on therapy for epilepsy. Cochrane Database Syst Rev 2015; 10:CD009472.
- Debus OM, Kurlemann G; Study group. Sulthiame in the primary therapy of West syndrome: a randomized double-blind placebo-controlled add-on trial on baseline pyridoxine medication. Epilepsia 2004; 45:103-108.
- Debus OM, Köhring J, Fiedler B, Franssen M, Kurlemann G. Add-on treatment with pyridoxine and sulthiame in 12 infants with West syndrome: an open clinical study. Seizure 2002; 11:381-383.
- And 8 more. Subscribe to see the full list
